Treat 4 Ramadan

• Research type

  Research Study

• Full title

  A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Liraglutide versus a Sulphonylurea and/or Pioglitazone

• IRAS ID

  68643

• Contact name

  Melanie Davies

• Eudract number

  2011-000284-27

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  The month of Ramadan is one of the five main pillars that make up the Muslim religion and is therefore an integral part of it. A large number of people, seventy-nine percent, with type 2 diabetes fast during this religious period despite the Qur'an excusing 'sick' people from their duty to fast during this holy month. Many Muslims with T2DM do not consider themselves 'sick' and are very keen to participate in fasting. These individuals would not usually discuss fasting with their health care professional, meaning no changes being made with respect to their lifestyle or medication prior to the start of the fasting period. This can put them at risk of experiencing severe hypoglycaemic (an unusually low level of sugar in the blood) events during this period amongst other risks. A new class of antidiabetic therapy has recently been licensed in the UK, the GLP-1 analogues. Liraglutide is one of these new classes of antidiabetic therapies. This therapy is associated with low risk of hypoglycaemia (an unusually low level of sugar in the blood) and also with lowering body weight whilst helping to stabilise blood sugar levels. This option may therefore be a safer option for those individuals with T2DM who wish to observe Ramadan compared to their usual care.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  11/EM/0005

• Date of REC Opinion

  16 Mar 2011

• REC opinion

  Further Information Favourable Opinion